Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. Its marketed products include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine; DUKORAL, an oral vaccine for diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli; and IXCHIQ/VLA1553, a single-dose live-attenuated chikungunya vaccine. The company also develops vaccine candidates such as VLA15 against Borrelia (Lyme disease), S4V2 against shigellosis, VLA1601 against Zika virus, VLA1554 against human metapneumovirus, VLA84 against primary symptomatic Clostridium difficile infection, PF-07307405 for Lyme disease prevention in individuals aged five years and older, and VLA2112 for Epstein-Barr virus. It sells products in the United States, Canada, Germany, Austria, the Nordics, the United Kingdom, France, the rest of Europe, and internationally. Founded in 1998, Valneva SE is based in Saint-Herblain, France.
Lyme vaccine advances in Europe, but UK chikungunya setback and wider loss weigh
▲
Lyme vaccine clears first European regulatory hurdle The EMA validated Pfizer and Valneva's application for their Lyme disease vaccine, starting the official review. If approved, it would be the first such vaccine in Europe and a major future revenue source for Valneva, which is the development partner. This is the biggest potential value driver in the period.
This is the main positive force behind VLA.PA, a new regulatory milestone for its most advanced pipeline asset.
UK pulls chikungunya vaccine approval over safety UK regulators revoked the marketing authorization for Valneva's chikungunya vaccine Ixchiq, and the company will not appeal. Valneva says the financial hit is minimal, but losing a whole approved market removes a revenue stream and raises questions about the product's safety profile elsewhere.
This is a new negative event that directly pressures VLA.PA shares and its commercial outlook.
First-half loss widens sharply on lower sales Valneva's net loss ballooned to €63.3 million from €20.8 million a year earlier, hurt by lower product sales, weak manufacturing volumes, and one-off costs including IXCHIQ contract termination and inventory write-offs. Cash rose to €121.5 million, and full-year guidance was kept, but profitability remains a concern.
The widening loss and weak sales are a core fundamental drag on the stock, even as cash and guidance hold.
Lyme trial data strong but not statistically clean The Phase 3 VALOR trial showed over 70% efficacy, but the primary analysis narrowly missed its required statistical threshold, while a second analysis passed. This means approval is not guaranteed and the review could face scrutiny, tempering the optimism around the EMA filing.
It is the key counterweight to the positive Lyme news, explaining why the regulatory win is not a sure thing.
Wolfspeed shares surged 20% after the company received a $1.5B, 30-year conditional loan commitment from the U.S. Department of War to support domestic development and production of silicon carbide materials and wide-bandgap power devices. Wolfspeed plans to use the financing to expand domestic low- and high-voltage GaN production, advance GaN-on-SiC RF epitaxial wafer technology, and develop radiation-hardening capabilities for SiC and GaN products, with manufacturing facilities in North Carolina, New York, and Arkansas; the loan terms require Wolfspeed to issue the DoW VWAP-based warrants for up to 7.5% of its fully diluted equity as financing tranches are funded. Applied Digital rose 5% after the neocloud provider reported upbeat FQ1 with revenue up 322% Y/Y and adjusted EBITDA of $64.4M. Valneva fell 3% after the UK Medicines and Healthcare Products Regulatory Agency revoked the marketing authorization for Ixchiq, its chikungunya vaccine, citing safety concerns; the company said it will not appeal and expects minimal financial impact. Marvell Technology slipped 2% despite Citi, Needham, and Morgan Stanley raising their price targets to $275, $400, and $300, respectively, after the chipmaker's investor day, where it projected fiscal 2031 revenue of $70B-$90B and at least $30 in earnings per share, and raised its FY2028 revenue outlook to $20B from $18B.
VLA.PA · Regulation · Negative Valneva fell 3% after the UK MHRA revoked the marketing authorization for its chikungunya vaccine Ixchiq over safety concerns.
WOLF · Capital · Positive Wolfspeed surged 20% after receiving a $1.5B, 30-year conditional loan commitment from the U.S. Department of War.
APLD · Capital · Positive Applied Digital rose 5% after reporting upbeat FQ1 with revenue up 322% Y/Y and adjusted EBITDA of $64.4M.
MRVL · Capital · Neutral Marvell slipped 2% despite Citi, Needham, and Morgan Stanley raising price targets after its investor day with raised FY2028 revenue outlook.
Pfizer and Valneva Lyme Vaccine PF-07307405 Enters EMA Review
The European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the experimental Lyme disease vaccine candidate from Pfizer and French biotech Valneva, and will now begin its official review. The filing rests on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older in high-incidence Lyme disease locations across the US, Canada, and Europe, which reported efficacy of over 70% in reducing confirmed Lyme disease cases with no safety issues detected. The statistical picture was less clean than the headline number: the first prespecified analysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%, while a second prespecified analysis showed 74.8% efficacy and did meet that threshold. Under the 2020 partnership and license agreement, Pfizer holds exclusive rights to produce and commercialize the vaccine if approved, with Valneva benefiting as development partner; Valneva says PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development. Pfizer shares were essentially flat on the news, and hedge fund ownership stood at 83 funds in the second quarter of 2026, unchanged from the first quarter, while Valneva's hedge fund exposure rose to 4 funds from 1. MAA validation means the application meets the standards for the EMA to begin evaluating it, not that approval is near or guaranteed, and formal reviews of this nature often take many months to complete.
Biotech & Genomic Medicine › Vaccines (Recombinant & Traditional) ▲Regulation
PFE · Regulation · Positive EMA validated Pfizer's Marketing Authorization Application for Lyme vaccine candidate PF-07307405, advancing it into formal regulatory review.
VLA.PA · Regulation · Positive EMA validated the MAA for PF-07307405, Valneva's most advanced Lyme vaccine candidate developed under its Pfizer partnership.
Pfizer Vaccine Milestones Could Shift Investment Narrative
Pfizer and BioNTech received U.S. FDA approval for their updated COMIRNATY COVID-19 vaccine targeting the XFG variant for high-risk individuals, while Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405 had its Marketing Authorization Application validated by the European Medicines Agency based on Phase 3 trial data. These milestones highlight Pfizer's role in infectious disease prevention, with the Lyme vaccine potentially becoming a key proof point for its pipeline. However, unresolved legal and pricing pressures, including the Depo Provera settlement program, remain overhangs. Pfizer's narrative projects $54.9 billion in revenue and $9.2 billion in earnings by 2029, implying a 4.6% yearly revenue decline and a $1.7 billion earnings increase from $7.5 billion today, yielding a $29.19 fair value, a 4% upside to its current price. Some analysts assume revenue could fall to about US$50.6 billion by 2029, reinforcing concerns that pipeline wins may not fully offset pricing pressure and patent losses.
Pfizer and Valneva Start EMA Review for Lyme Disease Vaccine
Pfizer and Valneva announced that the European Medicines Agency has validated the Marketing Authorization Application for their Lyme disease vaccine candidate, PF-07307405, initiating the regulatory assessment process for what could become a first-in-class vaccine for the disease in North America and Europe. The application is backed by Phase 3 efficacy data, with the companies highlighting an unmet medical need in Lyme disease prevention. This development is part of Pfizer's broader strategy to address widespread infectious diseases, complementing its existing vaccine portfolio. Investors should monitor the EMA's review milestones, including committee opinions and formal decisions expected into 2027, as well as any disclosures on manufacturing readiness and uptake expectations for the vaccine.
Pfizer and Valneva Lyme Disease Vaccine Application Validated by EMA
The European Medicines Agency has validated the Marketing Authorization Application for Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405, beginning its assessment of the submission. The application is based on efficacy of more than 70% observed in the Phase 3 VALOR trial, which enrolled 9,437 participants aged five and older across the U.S., Canada, and Europe, with no safety concerns identified. Pfizer's Chief Vaccines Officer Annaliesa Anderson said the vaccine could be the first of its kind in Europe, where Lyme disease affects more than 100,000 people annually and over 200 million live in risk areas. Valneva CEO Thomas Lingelbach called the acceptance a major milestone for the collaboration established in April 2020, under which Pfizer will exclusively manufacture and commercialize the vaccine if approved.
Valneva reported a first-half 2026 GAAP loss of €0.35 per share on revenue of €65.84 million, down 32.5% year over year, and reaffirmed its full-year guidance. The company expects 2026 product sales of €135 million to €150 million and total revenues of €145 million to €160 million, with product gross margins improving in the second half after one-off effects in the first half. Valneva also said it implemented a global restructuring to reduce cash burn through workforce reductions, reprioritized R&D, and streamlined operations, and agreed to sell its Nantes site in France for €6.2 million, with the transaction expected to close in September 2026. The company held a solid cash position of €121.5 million as of the end of June 2026.
Valneva shareholders approve all AGM resolutions, Dr. Gerd Zettlmeissl appointed Chair
Valneva SE announced that shareholders approved all resolutions recommended by the Board of Directors at its Annual General Meeting held in Lyon, France. Key resolutions included approval of the 2025 financial statements, renewal of share capital authorizations, and the transfer of the registered office to Lyon. Shareholders also reappointed five Board members: Anne-Marie Graffin, James Sulat, and Kathrin Jansen for one-year terms, James Connelly for a two-year term, and CEO Thomas Lingelbach for a three-year term. Following the meeting, the Board appointed independent director Dr. Gerd Zettlmeissl as Chair, succeeding Anne-Marie Graffin, who will continue as Vice-chair.
France
